Trinity Biotech

Trinity Biotech ROCE

The Return on Capital Employed (ROCE) of Trinity Biotech (TRIB) as of Nov 11, 2026 is 15.86 %. In the previous year, Return on Capital Employed (ROCE) was 60.16 % — a change of -73.64% (lower).

ROCE

15.86 %

YoY

-73.64%

Last updated:

In 2025, Trinity Biotech's return on capital employed (ROCE) was 15.86 %, a -73.64% increase from the 60.16 % ROCE in the previous year.

The Trinity Biotech ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
7.48 USD
Jan 1, 2019
18.50 USD
Jan 1, 2020
-3.70 USD
Jan 1, 2021
-1,234.48 USD
Jan 1, 2022
701.70 USD
Jan 1, 2023
112.93 USD
Jan 1, 2024
60.16 USD
Jan 1, 2025
15.86 USD
The Trinity Biotech ROCE history
YEARROCEYoY
15.86 %-73.64%
60.16 %-46.73%
112.93 %-83.91%
701.70 %-156.84%
-1,234.48 %+33,306.31%
-3.70 %-119.97%
18.50 %+147.22%
7.48 %-10.93%
8.40 %+21.95%
6.89 %+9.57%
6.29 %-31.34%
9.16 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Trinity Biotech's Return on Capital Employed (ROCE)

Trinity Biotech's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Trinity Biotech's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Trinity Biotech's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Trinity Biotech’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Trinity Biotech stock

Return on Capital Employed (ROCE) of Trinity Biotech is 15.86 % in 2025.

Return on Capital Employed (ROCE) of Trinity Biotech changed from 60.16 % to 15.86 %, representing a -73.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Trinity Biotech

All Key Metrics — Trinity Biotech